Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lung Neoplasms × canakinumab × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Rheumatoid Arthritis, Systemic Juvenile 1 Periodic Fevers Syndrome 1 Neoplasm Metastasis 1 Mevalonate Kinase Deficiency 1 Lung Neoplasms 1 Cryopyrin-Associated Periodic Syndromes 1 Carcinoma 1 Bronchiolitis Obliterans Syndrome 1 Arthritis, Juvenile 1 Arthralgia 1

Interventions

Carboplatin 55 Cisplatin 53 Radiotherapy 33 Paclitaxel 32 Docetaxel 29 Pemetrexed 27 Gemcitabine 26 Etoposide 22 pembrolizumab 20 Vinorelbine 17 Erlotinib Hydrochloride 10 Drug Therapy 10 durvalumab 9 Radiosurgery 9 Magnetic Resonance Spectroscopy 9 Specimen Handling 8 Nivolumab 8 Gefitinib 6 Cyclophosphamide 6 Bevacizumab 6 Vinblastine 5 Topotecan 5 Surgical Procedures, Operative 5 Standard of Care 5 Platinum 5 Ifosfamide 5 Dexamethasone 5 atezolizumab 4 Mitomycin 4 Immunoglobulin G 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05725343 2023-02-13

CANAL

Mario Negri Institute for Pharmacological Research

Phase 3 Terminated

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡